Not Signed In -
Olmesartan |
Benicar; olmesartan medoxomil |
Image:Olmesartan.png Olmesartan Systematic (IUPAC) name ? Identifiers CAS number 144689-63-4 ATC code C09CA08 PubChem 130881 DrugBank APRD00223 Chemical data Formula C29H30N6O6 Mol. weight 558.585 g/mol Pharmacokinetic data Bioavailability Rapid and complete absorption Metabolism Hepatic (cannot be removed by hemodialysis) Half life 13 hours Excretion Primarily fecal, small amount in urine Therapeutic considerations Pregnancy cat. C (D if use ...
Wikipedia - [full article]
Olmesartan Clinical Trials
- Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients with High Blood Pressure
ClinicalTrials.gov Identifier: NCT00151775 - Active, not recruiting
Hypertension
- Olmesartan Pediatric Pharmacokinetic (PK) Study
ClinicalTrials.gov Identifier: NCT00151814 - Recruiting
Hypertension
- ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
ClinicalTrials.gov Identifier: NCT00141453 - Active, not recruiting
Diabetic Nephropathy; type 2 diabeted mellitus; Proteinuria
- OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study
ClinicalTrials.gov Identifier: NCT00134160 - Active, not recruiting
Aged; Hypertension; Diabetes Mellitus Type 2; Cardiovascular Diseases
- Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
ClinicalTrials.gov Identifier: NCT00441350 - Not yet recruiting
Hypertension
- Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation
ClinicalTrials.gov Identifier: NCT00098137 - Recruiting
Heart Disease; Arrhythmia; Atrial Fibrillation
- Treatment of High Blood Pressure Using Olmesartan with Hydrochlorothiazide Compared to an ACE Inhibitor with a Calcium Channel Blocker
ClinicalTrials.gov Identifier: NCT00185120 - Completed
Hypertension
- Olmesartan and an Add-on Treatment in Patients With Mild to Moderate Hypertension
ClinicalTrials.gov Identifier: NCT00311155 - Recruiting
Essential Hypertension
- Olmesartan Medoxomil in Diabetes Mellitus
ClinicalTrials.gov Identifier: NCT00185159 - Active, not recruiting
Diabetes Mellitus, Type 2; Cardiovascular Disease; Kidney Disease
- An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
ClinicalTrials.gov Identifier: NCT00412932 - Recruiting
Hypertension
- Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)
ClinicalTrials.gov Identifier: NCT00454662 - Recruiting
Hypertension; Cardiovascular Disease; Diabetes
- Olmesartan as an Add-on to Amlodipine in Hypertension
ClinicalTrials.gov Identifier: NCT00220233 - Completed
Essential Hypertension
- Supplemental Benefit of ARB in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)
ClinicalTrials.gov Identifier: NCT00417222 - Recruiting
Chronic Heart Failure
- Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension
ClinicalTrials.gov Identifier: NCT00527514 - Recruiting
Hypertension
- Olmesartan in Essential Hypertension
ClinicalTrials.gov Identifier: NCT00185172 - Active, not recruiting
Essential Hypertension
- Amlodipine as Add-on to Olmesartan in Hypertension
ClinicalTrials.gov Identifier: NCT00220220 - Completed
Essential Hypertension
- Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
ClinicalTrials.gov Identifier: NCT00139698 - Completed
Essential Hypertension
- CVD Risk and Prevention in Early Glucose Intolerance
ClinicalTrials.gov Identifier: NCT00122447 - Recruiting
Impaired Glucose Tolerance (IGT)
- Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
ClinicalTrials.gov Identifier: NCT00430508 - Not yet recruiting
Essential Hypertension
- Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
ClinicalTrials.gov Identifier: NCT00430950 - Not yet recruiting
Essential Hypertension
- Olmesartan Medoxomil in Hypertension and Renal Impairment
ClinicalTrials.gov Identifier: NCT00151827 - Completed
Essential Hypertension; Renal impairment
- Olmesartan Medoxomil in Atherosclerosis
ClinicalTrials.gov Identifier: NCT00185185 - Completed
Essential Hypertension; Atherosclerotic Cardiovascular Disease
- VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
ClinicalTrials.gov Identifier: NCT00171015 - Completed
Hypertension
- An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
ClinicalTrials.gov Identifier: NCT00403481 - Completed
Hypertension
- Study of co-Administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension
ClinicalTrials.gov Identifier: NCT00185133 - Completed
Hypertension
- The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
ClinicalTrials.gov Identifier: NCT00185055 - Completed
Healthy
- A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis
ClinicalTrials.gov Identifier: NCT00382213 - Completed
Atherosclerosis
- A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
ClinicalTrials.gov Identifier: NCT00185094 - Completed
Hypertension; Insulin Resistance; Metabolic Syndrome
- A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
ClinicalTrials.gov Identifier: NCT00430638 - Completed
Hypertension
- Olmesartan Medoxomil and Diabetic Nephropathy
ClinicalTrials.gov Identifier: NCT00362960 - Completed
Type 2 Diabetes Mellitus; Diabetic Nephropathy; Proteinuria; Renal Disease
Resources
- Benicar (Drug Digest)
- Benicar Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
